Clinical trial 222892 AZUR 4
A Phase 2, open label, randomized study of neoadjuvant dostarlimab plus CAPEOX versus CAPEOX in participants with previously untreated T4N0 or Stage III MMRp/ MSS colon cancer
| Cancers | |
|---|---|
| Organ | Colon |
| Trial status | Trial open for recruitment |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 2 |
| Academic trial | Non |
| Sponsor | GSK |
| EudraCT Identifier | 2024-513441-36-00 |
| Last update |